IntelGenx Corp.
6425 Abrams Ville Street
Laurent
Quebec
H4S 1X9
Canada
Tel: 514-331-7440
Fax: 514-331-0436
Website: http://www.intelgenx.com/
Email: info@intelgenx.com
255 articles about IntelGenx Corp.
-
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
4/5/2024
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.
-
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
3/21/2024
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023.
-
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
2/20/2024
IntelGenx Corp. announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share, for a maximum Offering amount of $20,000,000.
-
IntelGenx Launches Preferred Share Regulation A Offering
2/20/2024
IntelGenx Corp. announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share, for a maximum Offering amount of $20,000,000.
-
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
2/5/2024
IntelGenx Corp. announced positive results from a proof-of-concept study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats.
-
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
12/18/2023
IntelGenx Corp. announced that it has entered into development and license agreements with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC.
-
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
12/5/2023
IntelGenx Technologies Corp. announces the closing of the previously announced subsequent non-brokered private placement of 750 units with atai Life Sciences AG for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units, following the Shareholder Approvals obtained at the special meeting held on November 28, 2023.
-
IntelGenx Announces Changes to its Board of Directors
12/4/2023
IntelGenx Technologies Corp. announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “ Board ”) effective December 2, 2023.
-
IntelGenx Announces Shareholder Approval of Financing Transactions - November 28, 2023
11/28/2023
IntelGenx Technologies Corp. is pleased to announce that, at its meeting held earlier , the shareholders voted to approve all proposals related to financing transactions involving atai Life Sciences AG previously disclosed by the Company on August 31, 2023.
-
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's DiseasePhase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024
11/14/2023
IntelGenx Corp. announced that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre have approved the planned clinical study to investigate the use of IntelGenx’s Montelukast VersaFilm® for the treatment of Parkinson’s Disease.
-
IntelGenx Reports Third Quarter 2023 Financial Results
11/9/2023
IntelGenx Technologies Corp. reported financial results for the third quarter ended September 30, 2023.
-
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
11/2/2023
IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.
-
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
9/21/2023
IntelGenx Corp. announced that it has received the first purchase order for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma.
-
IntelGenx Reports Second Quarter 2023 Financial Results
8/14/2023
IntelGenx Technologies Corp. reported financial results for the second quarter ended June 30, 2023.
-
IntelGenx Announces First Agreement for CDMO Packaging Services
8/10/2023
IntelGenx Corp. announced that it has entered into a binding term sheet agreement for the packaging of a pharmaceutical oral film product that its undisclosed CDMO customer is planning to commercialize in the United States.
-
IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
8/1/2023
IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm ® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”).
-
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
7/25/2023
IntelGenx Corp. today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned multicentre, randomized, double-blind, placebo-controlled clinical study (the “Study”) to investigate the use of IntelGenx’s Montelukast VersaFilm ® for the treatment of Parkinsons Disease.
-
IntelGenx Announces Voting Results on Election of Directors - July 06, 2023
7/6/2023
IntelGenx Technologies Corp. announces that, at the annual meeting of shareholders of the Company held on May 9, 2023, shareholders voted in favour of all items of business put forth by the Company, including the election of the directors, by a majority of the votes cast by shareholders present or represented by proxy.
-
IntelGenx Unveils Short-Term Commercial Objectives
5/31/2023
IntelGenx Corp. announced that it is executing on a plan focussed on near-term revenue generation.
-
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing
5/17/2023
IntelGenx Corp. a leading drug delivery company, is pleased to announce that it has received an amended Drug Establishment License from Health Canada, allowing the Company to conduct third-party testing.